The study involved three groups of 80 rats. Each group was divided in half to either receive radiation or no treatment. Then, each of those halves was divided into two more groups: one that received L-158,809, the compound similar to losartan, in its drinking water, and one group that received plain drinking water. The rats that received the drug received it before, during and for different time intervals 14, 28 or 54 weeks post-radiation.
In addition, a small group of rats continued to receive the drug for only five weeks after radiation.
Researchers found that administering L-158,809 before, during and for as little as five weeks after radiation either prevents or lessens the severity of radiation-induced cognitive impairment.
"The extent of cognitive impairment experienced by patients who undergo radiation therapy varies in terms of how it is recognized," Robbins said. "Sometimes the patient realizes that their short-term memory is fading or that they've lost the ability to multi-task. Instead of waking up in the morning and having a clear idea of what needs to get done that day, patients finds themselves having to write things down. They just can't keep thoughts in their brain. Sometimes it's a friend or partner that realizes the impairment, but once it is noticed, it is not going to improve. Cognitive decline resulting from radiation is not stable. It is a chronic, progressive condition."
An estimated 170,000 patients undergo radiation therapy annually to treat primary or metastatic brain tumors. At least 50 percent of adult patients who undergo the treatment and live six months or more post-radiation experience some level of cognitive decline. In children, the effect is even greate
'/>"/>
| Contact: Bonnie Davis bdavis@wfubmc.edu 336-716-4977 Wake Forest University Baptist Medical Center Source:Eurekalert |